Pure Bioscience, Inc. (PURE)
PURE is quoted over the counter, not listed on an exchange. Pure Bioscience, Inc. files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-16.
Profile
| Field | Value |
|---|---|
| Ticker | PURE, quoted over the counter |
| SEC CIK | 0001006028 |
| OTC Markets tier | OTCQB (price source, 2026-11-13) |
| SEC industry code | Miscellaneous Chemical Products |
| Business address | El Cajon, CA |
| Incorporated in | DE |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date of this report." | 10-K 2026-10-29 |
| Cash and burn | $569K cash; operating cash flow -$435K a quarter. | Report 2026-07-31 |
| Shares outstanding | 140,201,055 (2026-10-29); 111,886,473 a year earlier; 111,856,473 three years earlier. | Cover page 2026-10-29 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Weinberg & Company, P.A., Los Angeles, California, United States | PCAOB Form AP 2026-11-04 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q4 2026 2026-07-31 | $659K | -$610K | -$414K | $569K | $6.6M | $2.3M | 10-K 2026-10-29 |
| Q3 2026 2026-04-30 | $506K | -$624K | -$468K | $983K | $15.0M | $2.4M | 10-Q 2026-06-15 |
| Q2 2026 2026-01-31 | $443K | -$785K | -$606K | $198K | $11.7M | $2.4M | 10-Q 2026-03-17 |
| Q1 2026 2025-10-31 | $707K | -$464K | -$250K | $434K | $10.8M | $2.4M | 10-Q 2025-12-15 |
| Q4 2025 2025-07-31 | $763K | -$332K | -$456K | $334K | $11.2M | $2.2M | 10-K 2026-10-29 |
| Q3 2025 2025-04-30 | $489K | -$580K | -$512K | $540K | $4.9M | $1.9M | 10-Q 2026-06-15 |
| Q2 2025 2025-01-31 | $391K | -$798K | -$544K | $202K | $4.0M | $1.9M | 10-Q 2026-03-17 |
| Q1 2025 2024-10-31 | $555K | -$689K | -$503K | $346K | $3.5M | $1.8M | 10-Q 2025-12-15 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | POS AM | 2020-10-20 |
| Latest annual report | 10-K | 2026-10-29 |
| Latest quarterly / interim | 10-Q | 2026-06-15 |
| Latest current report | 8-K | 2026-10-29 |
| Latest proxy | DEF 14A | 2025-12-30 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier